多发性骨髓瘤市场：KOL 洞察

Multiple Myeloma - KOL Insight

出版日期: 年间契约型资讯服务 | 出版商:

FirstWord Group | 英文

价格

简介目录

随着治疗方案的显着进步，多发性骨髓瘤（MM）领域迅速发展。

本报告检视了全球多发性骨髓瘤市场，并提供了市场概况以及主要 KOL 的见解，强调将 Darzalex 纳入新诊断患者的四合疗法中，最近批准 Abecma 和 Carvykti 用于早期治疗系列，Tecvayli 和 Elrexfio 等 BCMA 靶向双特异性抗体的潜力，以及 Talvey 对于接受 BCMA 标靶治疗復发的患者的新角色。探索不断发展的 MM 治疗演算法及其对临床实践和药物开发的影响。

核准的治疗方法
- Abecma (idecabtagene vicleucel; BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel; J&J/Legend)
管道疗法
- Anitocabtagene autoleucel (CART-ddBCMA; Gilead/Arcellx); zevorcabtagene autoleucel (CARsgen); durcabtagene autoleucel (PHE885; Novartis); BMS-986393 (CC-95266; BMS)

双特异性抗体

核准的药物
- BCMA-targeting: Tecvayli (teclistamab; J&J) and Elrexfio (elranatamab; Pfizer)
- GPRC5D-targeting: Talvey (talquetamab; J&J)
研究药物
- BMCA-targeting: linvoseltamab (REGN5458; Regeneron); ABBV-383 (AbbVie); alnuctamab (BMS)
- FcRH5-targeting: cevostamab (Roche)

抗体药物偶联物（ADC）

研究药物
- Blenrep (belantamab mafodotin; GSK)

未来治疗趋势

主要见解摘要

附录

KOL报表

简介目录

The Multiple Myeloma (MM) landscape is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for MM, highlighting the consolidation of Darzalex in quadruplet regimens for newly diagnosed patients, the recent approval of Abecma and Carvykti for earlier treatment lines, the potential of BCMA-targeting bispecific antibodies like Tecvayli and Elrexfio, and the emerging role of Talvey for patients relapsing on BCMA-targeting therapies. Explore the evolving MM treatment algorithm and the implications for clinical practice and drug development.

Executive summary (1)

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs) (32)

Approved drugs (32)
- Darzalex (daratumumab; J&J) (14)
- Sarclisa (isatuximab; Sanofi) (18)

Immunomodulatory drugs (IMiDs) (8)

Pipeline drugs (8)
- Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS) (8)

Bcl-2 inhibitors (14)

Pipeline drugs (14)
- Venetoclax (Venclexta/Venclyxto; AbbVie/Roche) (14)

CAR T-cell therapies (36)

Approved therapies (26)
- Abecma (idecabtagene vicleucel; BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel; J&J/Legend) (26)
Pipeline therapies (10)
- Anitocabtagene autoleucel (CART-ddBCMA; Gilead/Arcellx); zevorcabtagene autoleucel (CARsgen); durcabtagene autoleucel (PHE885; Novartis); BMS-986393 (CC-95266; BMS) (10)

Bispecific antibodies (64)

Approved drugs (42)
- BCMA-targeting: Tecvayli (teclistamab; J&J) and Elrexfio (elranatamab; Pfizer) (27)
- GPRC5D-targeting: Talvey (talquetamab; J&J) (15)
Pipeline drugs (22)
- BMCA-targeting: linvoseltamab (REGN5458; Regeneron); ABBV-383 (AbbVie); alnuctamab (BMS) (13)
- FcRH5-targeting: cevostamab (Roche) (9)